Comparison of the Efficacy of Polyenes and Triazoles against Hematogenous Candida krusei Infection in Neutropenic Mice
Abstract
Candida krusei is reported to cause serious infections in immunocompromised patients, particularly those receiving prophylaxis with antifungal azoles. Treatment of this infection can be very challenging. The efficacy of amphotericin B, liposomal amphotericin B (three dosages), fluconazole, and D0870 (a new experimental oral bis-triazole) was assessed in a CF1 mouse model of hematogenous C. krusei infection. Increased survival time and reduced kidney fungal burden were achieved with treatment with amphotericin B at 2 mg/kg/day and liposomal amphotericin B at 8 and 15 mg/kg/day. D0870 at 25 mg/kg/day increased survival time but had no effect on clearance from organs, while the survival and clearance from organs of mice treated with fluconazole at a dose of 100 mg/kg/day did not differ from those of untreated animals. These findings suggest that deoxycholate and liposome-encapsulated amphotericin B are active against disseminated C. krusei infection in neutropenic mice and confirm the in vitro and in vivo resistance of this species to fluconazole.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Delivery of additional amphotericin B by use of a lipid-based preparation may be inadequate to overcome resistance in C. glabrata and C. krusei.
“Of importance, delivery of additional amphotericin B by use of a lipid-based preparation of amphotericin B may be inadequate to overcome this resistance [22].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [22]
Cites
Goodman, J. L., Winston, D. J., Greenfield, R. A., Chandrasekar, P. H., Fox, B. C., Kaizer, H., Shadduck, R. K., Shea, T. C., Stiff, P. J., Friedman, D. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261301 · Cited by 1,168 · see citing works
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937 · see citing works
Opportunistic Mycoses in the Immunocompromised Host: Experience at a Cancer Center and Review
Anaissie, E. J. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.supplement_1.s43 · Cited by 366 · see citing works
Self-citationTreatment of systemic fungal infections with liposomal amphotericin B.
Lopez-Berestein, G., Bodey, G. P., Fainstein, V., Keating, M. J., Frankel, L. S., Zeluff, B. J., Gentry, L. K., & Mehta, K. (1989) · PubMed · Cited by 176 · see citing works
Candidemia in Immunocompromised Patients
Meunier, F., Aoun, M., & Bitar, N. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.supplement_1.s120 · Cited by 171 · see citing works
Increased incidence of fungemia caused by Candida krusei
Merz, W. G., Karp, J. E., Schron, D., & Saral, R. (1986) · Journal of Clinical Microbiology · doi:10.1128/jcm.24.4.581-584.1986 · Cited by 139 · see citing works
Fluconazole andCandida kruseiFungemia
Persons, D. A., Laughlin, M. A., Tanner, D., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251814 · Cited by 99 · see citing works
Anaissie, E., Paetznick, V. L., & Bodey, G. P. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.8.1641 · Cited by 90 · see citing works
Self-citationMcQuillen, D. P., Zingman, B. S., Meunier, F., & Levitz, S. M. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.2.472 · Cited by 87 · see citing works
Fisher, M. A., Shen, S. H., Haddad, J., & Tarry, W. F. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.9.1443 · Cited by 81 · see citing works
Morace, G., Manzara, S., & Dettori, G. (2009) · Chemotherapy · doi:10.1159/000238828 · Cited by 63 · see citing works
A comparison of experimental pathogenicity ofCandidaspecies in cyclophosphamide-immunodepressed mice
Bistoni, F., Vecchiarelli, A., Cenci, E., et al. (1984) · Medical Mycology · doi:10.1080/00362178485380661 · Cited by 51 · see citing works
Candida krusei infectious arthritis
Nguyen, V. Q., & Penn, R. L. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90660-7 · Cited by 33 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · see citing works
Practice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927 · see citing works
Antifungal drug resistance of pathogenic fungi
Kontoyiannis, D. P., & Lewis, R. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08162-x · Cited by 553 · see citing works
Pfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521 · see citing works
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377 · see citing works
- Authors
- Karyotakis, N. C., Anaissie, E. J., Hachem, R., Dignani, M. C., & Samonis, G.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Anaissie, E. J.
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1993-11-01
- Volume
- 168
- Issue
- 5
- Pages
- 1311-1313
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2140058311
- Cited by
- 40
- References
- 13
- Citations by year
- 2023: 1 · 2019: 2 · 2013: 1
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA-16672, P30CA016672)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
- Keywords
- Candida krusei, neutropenic mice, amphotericin B, liposomal amphotericin B, fluconazole, antifungal efficacy, fluconazole resistance, kidney fungal burden, disseminated fungal infection
- MeSH terms
- Amphotericin B, Animals, Candidiasis, Hematopoiesis, Immunosuppression Therapy, Liposomes, Male, Neutropenia, Fluconazole, Survival Analysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
